YvonneA.EfeberaMDMPH

Hematology • Columbus, OH

Associate Professor, Dept of Internal Medicine, Division of Hematology, The Ohio State University.

Join to view full profile

Dr. Efebera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Efebera's full profile

Already have an account?

Office
500 Thomas Ln
Columbus, OH 43214
Phone+1 614-566-2500

Fax+1 614-293-4812

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Pennsylvania State University College of MedicineClass of 1998

Certifications & Licensure

OH State Medical License 2000 - 2025
TX State Medical License 2008 - 2022
MA State Medical License 2004 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Dec 10
Completed
Phase 2
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease Start of enrollment: 2012 Feb 20
Recruiting
Brentuximab Vedotin for Steroid Refractory GvHD Start of enrollment: 2012 Jul 01
Completed
Phase 1
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Mar 03
Terminated
Phase 1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Mar 21
Terminated
Phase 2
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Start of enrollment: 2020 Dec 22
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10
59 citations
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Matthew J Hartwell, Umut Özbek, Ernst Holler, Anne S Renteria, Hannah Major-Monfried
JCI Insight. 2017-02-09
49 citations
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
Alberto Rocci, Craig C. Hofmeister, Susan Geyer, Andrew Stiff, Manuela Gambella
Leukemia. 2014-05-12

Abstracts/Posters

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Restoring Functional Deficits in Older Adults with Hematologic Malignancy
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory ...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018